Peptides / Growth hormone axis

Synthetic analog · 6 amino acids · 887 Da

Hexarelin

Not approvedBanned in sport

Hexarelin is a synthetic six-amino-acid peptide related to GHRP-6 that acts on the ghrelin receptor to release growth hormone. It is not approved and is banned in sport, and studies in people measured growth hormone, stress hormones and pituitary hormones. PepBank shows 498 results on hexarelin from 94 studies in people, and 613 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Hex, EP-23905, MF-6003, Examorelin, Examorelina, Examoreline

6 amino acids, from first to lastHXAWFK

Evidence level: Some studies in people498 of 1,112 results come from studies in people.

Results in people

498

45% of 1,112 results

Results in animals

407

37% of 1,112 results

Results in lab cells

206

19% of 1,112 results

From computer models

under 1% of 1,112 results

Overview

Hexarelin at a glance

What it is	Synthetic analog, 6 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S2.2.4)
Studies	245 studies with results. 219 of them gave hexarelin, with 1,112 results. 498 in people407 in animals206 in lab cells1 from computer models
Best study in people	Randomized controlled trial with 16 people (1997)
Clinical trials	None registered
Community use	Raising growth hormone release; Muscle gain and fat loss (body composition); Healing of injuries and joints; Sleep

The science

What is hexarelin?

Synthetic hexapeptide that activates the ghrelin receptor and releases growth hormone; it is a GHRP-6 analog. It is not an approved medicine.

Amino acids in one chain

Hexarelin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 6 amino acidsFrom the first amino acid to the last

H1XAWF5+K

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Hexarelin is a synthetic analog of 6 amino acids, with no ring, 4 changed amino acids.

Formula

C₄₇H₅₈N₁₂O₆

Molecular weight

887 g/mol

CAS number

140703-51-1

Targets

Growth hormone secretagogue receptor type 1a (ghrelin receptor) (gene GHSR): agonistEvidence: primary literaturePlatelet glycoprotein 4 (CD36, scavenger receptor) (gene CD36): binds (ligand); activation by hexarelin causes a coronary vasoconstrictor response in rat heartsEvidence: primary literature

Development

Mediolanum Farmaceutici (Italy). AdisInsight lists Mediolanum as originator. Wikipedia also says it was developed by Mediolanum Farmaceutici (citing a pharmacology dictionary). AdisInsight also records that Europeptides was acquired from Zentaris AG by Ardana Bioscience on 2002-08-25. Highest phase: phase 2.

Identifiers

PubChem 6918297, ChEMBL CHEMBL108335, UNII 09QF37C617, DrugBank DB19510, IUPHAR 1100

Full sequence, SMILES and InChIKey

Three-letter sequence
H-His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2

InChIKey
RVWNMGKSNGWLOL-GIIHNPQRSA-N

SMILES
Cc1c(C[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H](Cc4ccccc4)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@H](Cc5cnc[nH]5)N)c6ccccc6[nH]1

See charge, composition and 3D structure on the Scientific page

The evidence

What hexarelin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people498 of 1,112 results come from studies in people.

Growth hormone and growth

372 results · 273 in people · 89 animal · 10 lab

Hexarelin raised the growth hormone peak less in women with anorexia nervosa than in healthy women. Journal of endocrinological investigation, 1997

Top results

Hexarelin raised the growth hormone peak less in women with anorexia nervosa than in healthy women. (Journal of endocrinological investigation, 1997)
In short children before puberty, hexarelin nasal doses sped up growth. (Clinical endocrinology, 1995)
In healthy young men, hexarelin raised growth hormone. (The Journal of clinical endocrinology and metabolism, 1999)

Hormones

178 results · 169 in people · 3 animal · 6 lab

In healthy young men, hexarelin raised ACTH. The Journal of clinical endocrinology and metabolism, 1999

Top results

In healthy young men, hexarelin raised ACTH. (The Journal of clinical endocrinology and metabolism, 1999)
In healthy people, hexarelin raised prolactin levels more than placebo. (Clinical endocrinology, 1996)
In healthy men, higher doses of hexarelin raised prolactin more, up to a plateau at the 1.0 microgram/kg dose. (The Journal of clinical endocrinology and metabolism, 1996)

Heart and blood vessels

184 results · 25 in people · 110 animal · 49 lab

In healthy men, hexarelin increased the heart's pumping fraction. Journal of endocrinological investigation, 1999

Top results

In healthy men, hexarelin increased the heart's pumping fraction. (Journal of endocrinological investigation, 1999)
In healthy men, hexarelin did not change blood pressure. (Journal of endocrinological investigation, 1999)
In rats with the pituitary gland removed, hexarelin reduced the strong response of aortic tissue to endothelin-1. (Journal of cardiovascular pharmacology, 1999)

Bones and joints

28 results · 6 in people · 19 animal · 3 lab

In short children before puberty, hexarelin nasal doses raised blood phosphate. Clinical endocrinology, 1995

Top results

In short children before puberty, hexarelin nasal doses raised blood phosphate. (Clinical endocrinology, 1995)
In adults, one bone formation marker was higher after 16 weeks of hexarelin than at the start. (The Journal of clinical endocrinology and metabolism, 1998)
In children with short stature, a week of hexarelin nasal doses raised blood alkaline phosphatase. (Journal of pediatric endocrinology & metabolism, 1995)

Weight and appetite

29 results · 5 in people · 23 animal · 1 lab

In short children before puberty, hexarelin nasal doses reduced skinfold thickness. Clinical endocrinology, 1995

Top results

In short children before puberty, hexarelin nasal doses reduced skinfold thickness. (Clinical endocrinology, 1995)
In adults, body fat did not change significantly after 16 weeks of hexarelin. (The Journal of clinical endocrinology and metabolism, 1998)
In healthy young men, hexarelin caused a small short-term rise in appetite. (The Journal of clinical endocrinology and metabolism, 1999)

Blood sugar

15 results · 3 in people · 11 animal · 1 lab

In 11 healthy young adults, hexarelin did not change blood glucose. The Journal of clinical endocrinology and metabolism, 2001

Top results

In 11 healthy young adults, hexarelin did not change blood glucose. (The Journal of clinical endocrinology and metabolism, 2001)
In 11 healthy young adults, hexarelin did not change blood insulin. (The Journal of clinical endocrinology and metabolism, 2001)
In short boys before puberty, intranasal hexarelin was followed by a rise in blood insulin. (European journal of endocrinology, 1997)

All 245 hexarelin studies by area Open the Scientific page

Key hexarelin studies

Studies in people come first, then studies in animals and in the lab.

People
Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa
Giusti et al. 1997 · Journal of endocrinological investigation · 16 people · cited by 7
7 results
People
The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin
Korbonits et al. 1999 · The Journal of clinical endocrinology and metabolism · 15 people · cited by 62
9 results
People
Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects
Arvat et al. 1994 · The Journal of clinical endocrinology and metabolism · 15 people · cited by 50
4 results
People
Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients
Ciccarelli et al. 1996 · Clinical endocrinology · 14 people · cited by 22
7 results
People
Growth hormone-releasing activity of hexarelin in humans. A dose-response study
Imbimbo et al. 1994 · European journal of clinical pharmacology · 12 people · cited by 30
10 results

All 245 Hexarelin studies

Hexarelin clinical trials

ClinicalTrials.gov lists no trial of hexarelin. A trial under another name may exist.

Status and safety

Is hexarelin approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.4.

No. Not approved for any use. Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 22 Oct 2026). Banned in sport (WADA S2.2.4).

Laws and labels change, so check the regulator for the current status.

Hexarelin side effects and safety

PepBank has 21 safety results from studies of hexarelin. 13 of them come from studies in people.

Safety results from studies (21)

A single hexarelin injection did not change mean blood pressure in healthy adults or in the two patient groups. (Endocrine, 2001)
In men with growth hormone deficiency and in healthy men, hexarelin did not change catecholamine levels. (European journal of pharmacology, 1999)
In healthy older adults, neither nasal nor oral hexarelin caused any side effect in this small study. (European journal of endocrinology, 1996)
No one in the study had side effects after hexarelin. (The Journal of clinical endocrinology and metabolism, 1995)
Long-term hexarelin did not change cortisol in the urine. (Clinical endocrinology, 1999)
In children with short stature, the TSH rise with hexarelin showed no sign of lower thyroxine. (Journal of pediatric endocrinology & metabolism, 1995)
A single hexarelin injection did not change heart rate in healthy adults or in the two patient groups. (Endocrine, 2001)
In men with growth hormone deficiency and in healthy men, hexarelin did not change mean blood pressure. (European journal of pharmacology, 1999)
In men with growth hormone deficiency and in healthy men, hexarelin did not change cardiac output. (European journal of pharmacology, 1999)
Long-term hexarelin did not change basal cortisol. (Clinical endocrinology, 1999)
Long-term hexarelin did not change the ACTH response. (Clinical endocrinology, 1999)
Long-term hexarelin did not change cortisol binding globulin. (Clinical endocrinology, 1999)
Long-term hexarelin did not change the prolactin response. (Clinical endocrinology, 1999)
In female mice that were not pregnant, hexarelin lowered the ovulation rate. (Reproduction, fertility, and development, 2010)
In rats, hexarelin under the skin made stomach ulcers from indomethacin worse by 40%, while ghrelin did not. (Peptides, 2004)
In female mice given the higher hexarelin dose, fewer fetuses developed for each egg released. (Reproduction, fertility, and development, 2012)
In mice, hexarelin given during pregnancy impaired learning in the offspring, and female offspring were more affected. (Reproduction, fertility, and development, 2010)
In adult mice, long-term hexarelin impaired learning, similar to the effect seen in the offspring. (Reproduction, fertility, and development, 2010)
In female mice, hexarelin at both doses showed only a downward trend in pregnancy rate. (Reproduction, fertility, and development, 2012)
In male mice, hexarelin at both doses showed only a downward trend in the share of females made pregnant. (Reproduction, fertility, and development, 2012)
In mice of both sexes, hexarelin had no significant effect on the other reproductive measures checked. (Reproduction, fertility, and development, 2012)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
2 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 15	Arvat 1994
2 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 14	Ciccarelli 1996
0.5, 1 and 2 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 12	Imbimbo 1994
0.5 microgram/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 12	Imbimbo 1994
1 microgram/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 12	Imbimbo 1994
2 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 12	Imbimbo 1994
2 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 12	Korbonits 1995
0.5 microgram/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 12	Massoud 1997
2 microgram kg-1	Human	human	intravenous	Not reported	Randomized trial in people · n = 9	Coiro 2000
2 micrograms/kg	Human	human	Not reported	single injection	Randomized trial in people · n = 8	Loche 1997
1.0 microg/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 7	Arvat 2001
2.0 microg/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 7	Arvat 1997
2 micrograms/kg	Human	human	intravenous	single dose	Randomized trial in people · n = 6	Arvat 1996
2.0 microg/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 6	Gianotti 2001
0.25, 0.5 and 2.0 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 6	Arvat 1997
0.25 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 6	Arvat 1997
0.5 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 6	Arvat 1997
2.0 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 6	Arvat 1997
0.25 and 0.5 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 6	Arvat 1997
1 microgram/kg body weight	Human	human	Not reported	Not reported	Randomized trial in people · n = 6	Sartorio 1997
1 microgram/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 6	Sartorio 1995
1 microgram/kg	Human	human	intravenous	two boluses 60 or 120 minutes apart	Randomized trial in people · n = 6	Massoud 1996
0-1.0 microgram/kg	Human	human	intravenous	single dose	Randomized trial in people	Massoud 1996
2.0 micrograms/kg	Human	human	intravenous	single dose	Trial in people without random groups · n = 60	Arvat 1997
2 micrograms/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 45	Loche 1995
2.0 microg/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 42	Arvat 1998
2 micrograms/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 38	Arvat 1997
2.0 micrograms/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 32	Grottoli 1999
1.0, 2.0 and 3.0 micrograms/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 28	Arvat 1998
2.0 microg/kg	Human	human	intravenous	single acute dose, measured up to 60 min	Trial in people without random groups · n = 26	Broglio 2001
2 micrograms/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 25	Loche 1997
2 microg/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 24	Maghnie 1998
2.0 microg/kg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 23	Grottoli 2000
1.5 micrograms per kg of body weight	Human	human	subcutaneous	single bolus	Trial in people without random groups · n = 21	Rahim 1998
2 micrograms/kg	Human	human	intravenous	single dose	Trial in people without random groups · n = 20	Grottoli 1997
2 microg/kg	Human	human	Not reported	Not reported	Trial in people without random groups · n = 19	Korbonits 1999
2 microg/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 19	Guzzaloni 2000
2 micrograms/kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 18	Bartolotta 1997
100 micrograms	Human	human	intravenous bolus	single dose	Trial in people without random groups · n = 17	Giustina 1996
2 micrograms/Kg	Human	human	intravenous	Not reported	Trial in people without random groups · n = 17	Cappa 1998

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Community sources describe hexarelin as the strongest of the GHRP-type growth hormone secretagogues. People inject it under the skin, often on an empty stomach, once to three times a day in short or cycled blocks. They report that its effect fades with continued use.

Reported routines and cautions

What people use it for

Raising growth hormone releaseS1S2S3
Muscle gain and fat loss (body composition)S2S5
Healing of injuries and jointsS5
SleepS1

Reported regimens

Regimens that community sources report for Hexarelin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
General growth hormone release	subcutaneous injectionS1 says it is injected on an empty stomach	100 to 200 mcg per dose	two to three times daily	5 weeks (S3) to 8 to 12 weeks with a 4 to 6 week break (S1)	3 sources agree on 100-200 mcg per dose. Frequency (2 to 3 times daily) and duration (5 weeks against 8 to 12 weeks) differ. S1 is a wiki that summarises reports from other sites and carries a supplier ranking (affiliate). S2 and S3 are single-user posts on pages that advertise sellers.	S1S2S3
Lower dose stacked with Mod GRF 1-29 (a GHRH analog)	subcutaneous injectionroute is given by S1	50 to 100 mcg per dose of hexarelin, with 100 mcg of Mod GRF 1-29	2 to 3 times daily (S1); morning plus before or after training (S2)	8 to 12 weeks (S1)	2 sources agree on 100 mcg of Mod GRF 1-29 with 50 to 100 mcg of hexarelin. S1 is an affiliate wiki. S2 is a single-user post on a page that advertises a seller.	S1S2
Higher daily totals in short blocks	Not statedthe quotes do not state the route	200 to 500 mcg per day	S3 reports 200 mcg twice daily; the other sources give a daily total	4 weeks on and 4 weeks off (S4); 5 weeks (S3)	sources differ: 200 to 500 mcg a day. Each figure comes from one user's post.	S3S4 S5
Low dose daily use for months with one day off a week	Not statedthe quotes do not state the route	50 to 100 mcg per dose	daily, 2 to 3 times a day, with one day a week off	months	single source (one user's posts). That user also advertises a seller with discount codes in the first post.	S2

Reported side effects

tingling or numbness in the hands or limbsS1S2S3
tiredness or sleepiness after a doseS3
symptoms like raised cortisol (water retention, mood changes)S1
tight midsection and water retentionS2
raised prolactin (users add a prolactin-lowering step)S1S3
weaker effect after weeks of continuous use (desensitization)S1

Reported benefits (claims, not shown in trials)

stronger growth hormone response than ipamorelin or GHRP-2S1S2
deeper sleep when dosed before bedS1
faster healing of injuriesS5
muscle gain and some fat lossS2S5

Cautions

Sources say the growth hormone response fades with continued use, so users cycle or take days off.S1S2
A published 16-week trial (1.5 microgram per kg under the skin twice daily) found a partial, reversible fall in the growth hormone response to hexarelin. It was back to baseline 4 weeks after the last dose.S6
One wiki says cortisol and prolactin rises are larger than with selective GHRPs, and that it is recommended only for experienced GHRP users.S1
One wiki says product quality varies between vendors.S1
Community amounts are not from trials. They are reports from forum users.S1S2

Status notes

Hexarelin is not an approved medicine. It is not named in the FDA 503A or 503B compounding lists (documents updated 2026-05-14 and 2025-03-21).S7 S8
WADA names examorelin (hexarelin) in S2.2.4 of the 2026 List. It is prohibited at all times.S9

Community sources

S1Hexarelin Community Protocols & Anecdotal Reportspeptideprotocolwiki.comcarries seller links, not linked
S2Hexarelin, the strongest GHRP (forum thread)elitefitness.comcarries seller links, not linked
S3CJC-DAC, Hexarelin and Ipamorelin Log (forum thread)anabolicsteroidforums.comcarries seller links, not linked
S4Hexarelin and prolactin... Do I need PCT? (forum thread) (opens in a new tab)musclechemistry.com
S5Hexarelin Profile (forum post with user notes) (opens in a new tab)musclechemistry.com
S6Growth hormone status during long-term hexarelin therapy (J Clin Endocrinol Metab 1998) (opens in a new tab)europepmc.org
S7FDA 503A categories of bulk drug substances (opens in a new tab)fda.gov
S8FDA 503B categories of bulk drug substances (opens in a new tab)fda.gov
S9WADA 2026 Prohibited List (opens in a new tab)wada-ama.org

Gaps

No approved label dose exists, so there is no label regimen. S1 also lists a 100 mcg once-daily 'tolerance assessment' for the first 1 to 2 weeks and a 100 to 200 mcg once-daily 'cardioprotective' protocol for 8 to 12 weeks; both come from the affiliate wiki alone and are not written as regimens. S2 and S3 promote sellers (S2 with discount codes, S3 with a banner); PepBank does not link to sellers. R4 rests on S2 alone. Longecity and Meso-Rx threads on hexarelin were not found. PepAtlas and looksmax.org threads could not be fetched (certificate error and HTTP 403). Reddit is not used. Several posts are old (2009 to 2016); the S1 wiki page is dated 2026-02-16.

Questions and more

Ask a question about hexarelin

The answer links to every study it uses.

What does the evidence say about hexarelin?Is hexarelin tested in people?Compare with GHRP-6 Compare with MK-677 (ibutamoren)

Sources

Database: PepBank data for hexarelin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about hexarelin

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Hexarelin

Not approvedBanned in sport

Also known as Hex, EP-23905, MF-6003, Examorelin, Examorelina, Examoreline

What it is

Synthetic analog, 6 amino acids

Approval

Not approved for any use

In sport

Banned in sport (WADA S2.2.4)

Studies

245 studies with results. 219 of them gave hexarelin, with 1,112 results.
498 in people407 in animals206 in lab cells1 from computer models

Best study in people

Randomized controlled trial with 16 people (1997)

Clinical trials

None registered

Community use

Raising growth hormone release; Muscle gain and fat loss (body composition); Healing of injuries and joints; Sleep

Dose as reported

Class

Species

Route

Duration

Design

Source

2 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 15

Arvat 1994

2 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 14

Ciccarelli 1996

0.5, 1 and 2 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 12

Imbimbo 1994

0.5 microgram/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 12

Imbimbo 1994

1 microgram/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 12

Imbimbo 1994

2 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 12

Imbimbo 1994

2 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 12

Korbonits 1995

0.5 microgram/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 12

Massoud 1997

2 microgram kg-1

Human

human

intravenous

Not reported

Randomized trial in people · n = 9

Coiro 2000

2 micrograms/kg

Human

human

Not reported

single injection

Randomized trial in people · n = 8

Loche 1997

1.0 microg/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 7

Arvat 2001

2.0 microg/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 7

Arvat 1997

2 micrograms/kg

Human

human

intravenous

single dose

Randomized trial in people · n = 6

Arvat 1996

2.0 microg/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 6

Gianotti 2001

0.25, 0.5 and 2.0 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 6

Arvat 1997

0.25 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 6

Arvat 1997

0.5 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 6

Arvat 1997

2.0 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 6

Arvat 1997

0.25 and 0.5 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 6

Arvat 1997

1 microgram/kg body weight

Human

human

Not reported

Randomized trial in people · n = 6

Sartorio 1997

1 microgram/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 6

Sartorio 1995

1 microgram/kg

Human

human

intravenous

two boluses 60 or 120 minutes apart

Randomized trial in people · n = 6

Massoud 1996

0-1.0 microgram/kg

Human

human

intravenous

single dose

Randomized trial in people

Massoud 1996

2.0 micrograms/kg

Human

human

intravenous

single dose

Trial in people without random groups · n = 60

Arvat 1997

2 micrograms/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 45

Loche 1995

2.0 microg/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 42

Arvat 1998

2 micrograms/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 38

Arvat 1997

2.0 micrograms/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 32

Grottoli 1999

1.0, 2.0 and 3.0 micrograms/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 28

Arvat 1998

2.0 microg/kg

Human

human

intravenous

single acute dose, measured up to 60 min

Trial in people without random groups · n = 26

Broglio 2001

2 micrograms/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 25

Loche 1997

2 microg/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 24

Maghnie 1998

2.0 microg/kg

Human

human

Not reported

Trial in people without random groups · n = 23

Grottoli 2000

1.5 micrograms per kg of body weight

Human

human

subcutaneous

single bolus

Trial in people without random groups · n = 21

Rahim 1998

2 micrograms/kg

Human

human

intravenous

single dose

Trial in people without random groups · n = 20

Grottoli 1997

2 microg/kg

Human

human

Not reported

Trial in people without random groups · n = 19

Korbonits 1999

2 microg/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 19

Guzzaloni 2000

2 micrograms/kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 18

Bartolotta 1997

100 micrograms

Human

human

intravenous bolus

single dose

Trial in people without random groups · n = 17

Giustina 1996

2 micrograms/Kg

Human

human

intravenous

Not reported

Trial in people without random groups · n = 17

Cappa 1998

Context

Route

Amount

How often

How long

Agreement

Sources

General growth hormone release

subcutaneous injectionS1 says it is injected on an empty stomach

100 to 200 mcg per dose

two to three times daily

5 weeks (S3) to 8 to 12 weeks with a 4 to 6 week break (S1)

3 sources agree on 100-200 mcg per dose. Frequency (2 to 3 times daily) and duration (5 weeks against 8 to 12 weeks) differ. S1 is a wiki that summarises reports from other sites and carries a supplier ranking (affiliate). S2 and S3 are single-user posts on pages that advertise sellers.

S1S2S3

Lower dose stacked with Mod GRF 1-29 (a GHRH analog)

subcutaneous injectionroute is given by S1

50 to 100 mcg per dose of hexarelin, with 100 mcg of Mod GRF 1-29

2 to 3 times daily (S1); morning plus before or after training (S2)

8 to 12 weeks (S1)

2 sources agree on 100 mcg of Mod GRF 1-29 with 50 to 100 mcg of hexarelin. S1 is an affiliate wiki. S2 is a single-user post on a page that advertises a seller.

S1S2

Higher daily totals in short blocks

Not statedthe quotes do not state the route

200 to 500 mcg per day

S3 reports 200 mcg twice daily; the other sources give a daily total

4 weeks on and 4 weeks off (S4); 5 weeks (S3)

sources differ: 200 to 500 mcg a day. Each figure comes from one user's post.

S3S4 S5

Low dose daily use for months with one day off a week

Not statedthe quotes do not state the route

50 to 100 mcg per dose

daily, 2 to 3 times a day, with one day a week off

months

single source (one user's posts). That user also advertises a seller with discount codes in the first post.

Hexarelin

Hexarelin at a glance

What is hexarelin?

Hexarelin structure and chemistry

What hexarelin studies show

Growth hormone and growth

Hormones

Heart and blood vessels

Bones and joints

Weight and appetite

Blood sugar

Key hexarelin studies

Hexarelin clinical trials

Is hexarelin approved?

Hexarelin side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about hexarelin

Related peptides

Sources

Hexarelin

Hexarelin at a glance

What is hexarelin?

Hexarelin structure and chemistry

What hexarelin studies show

Growth hormone and growth

Hormones

Heart and blood vessels

Bones and joints

Weight and appetite

Blood sugar

Key hexarelin studies

Hexarelin clinical trials

Is hexarelin approved?

Hexarelin side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about hexarelin

Related peptides

Sources